HOME >> MEDICINE >> NEWS
Highlights summarized for movement disorders research at 56th annual meeting

ST. PAUL, Minn. (May 4, 2004) - Movement disorders are neurological diseases that cause aberrant movement, and include Parkinson's disease, tremor, restless legs syndrome and dystonia. Among the largest of subspecialties within neurology, they are also the subject of some of the most intense research. At the 56th Annual Meeting of the American Academy of Neurology, these were some of the highlights of new research presented in movement disorders:

Parkinson's Disease Basic Science

Parkinson's disease (PD) is caused by progressive cell death in a small part of the brain that helps control movements by releasing the chemical dopamine. Levodopa is the mainstay of PD therapy, but must be converted in the brain into dopamine by an enzyme called AADC (aromatic L-amino acid decarboxylase). Researchers in California presented results of a long-term gene therapy trial in monkeys with a condition that mimics PD. They introduced the gene for AADC into the affected parts of the brains of four monkeys, using a virus as a carrier. After three-and-a-half years, the gene was still making the enzyme widely throughout the affected part of the brain, and the monkeys required much less levodopa to control their PD symptoms. Importantly, the dose of levodopa could be lowered to the point that it no longer caused uncontrolled movements called dyskinesias, which are a major complication of late-stage PD treatment. These promising results suggest that this approach may work in PD patients as well. [S28.004]

Parkinson's Disease Genetics

Most cases of PD are thought to result from a combination of genes and environmental factors such as pesticides and other poisons. Genes that cause PD by themselves are rare. An exception is found in a pair of families from Greece and Italy, who carry a mutation in a gene for a brain protein called alpha-synuclein. While this mutation is exceedingly rare, it has already taught PD researchers much about the dise
'"/>

Contact: Kathy Stone
kstone@aan.com
651-695-2763
American Academy of Neurology
4-May-2004


Page: 1 2 3 4 5

Related medicine news :

1. Highlights of the December Journal of the American Dietetic Association
2. Highlights of the September Journal of the American Dietetic Association
3. Highlights of Washington University Alzheimers Research at National Conference
4. Highlights of June Journal of the American Dietetic Association
5. Effective Clinical Practice, Jan/Feb. 2002 Highlights
6. Study Highlights Flu Risks For Women With Chronic Illness
7. Maxim Phase II Clinical Trial Highlights Substantial Increase In Leukemia-FreeSurvival For Acute Myelogenous Leukemia Patients
8. Speakers cramp, a new type of involuntary mouth-, lip-muscle movement
9. New system for the analysis of facial movement in three dimensions
10. Rutgers-Newark researchers link early movement, brain development
11. GSKS Requip(R) (ropinirole HCl) significantly reduces periodic leg movements in patients with RLS

Post Your Comments:
(Date:5/21/2013)... agency for scientific and technological research So Paulo Research ... announced an investment estimated in US$ 680 million to ... a period of up to eleven years, subject to ... , Funding for the 17 RIDCs will come from ... support personnel, and infrastructure). Host institutions will participate in ...
(Date:5/21/2013)... York, New York (PRWEB) May 21, 2013 ... Vinci surgery robot lawsuit is nearing its conclusion ... According to Bloomberg.com, during closing statements yesterday, an attorney ... dealership, alleging the company wanted to tie sales and ... do all the training to keep control of surgeons, ...
(Date:5/21/2013)... Today, Zane Benefits, Inc. published a ... accounts. Zane Benefits, which provides comprehensive and flexible alternatives ... in defined contribution and http://HRA ... to Zane Benefits’ website, the Affordable Care Act (known ... in 2010 and impacts many areas of health care ...
(Date:5/21/2013)... Two executives from human resources and ... which strategies can be most effective to better manage ... members who are taking them, in an upcoming May ... to Manage Specialty Drugs to Reduce Costs and Ensure ... main driver for rising prescription drug costs, which are ...
(Date:5/21/2013)... May 21, 2013 While North Carolina ... with comprehensive travel guides. Brunswick Plantation & Golf Resort ... that include access to 27 holes of "Top10" championship ... in North Carolina, knowing the Top 10 ... takes away the overwhelming task of selecting the course ...
Breaking Medicine News(10 mins):Health News:Research at the cutting edge of knowledge 2Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 2Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 3Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 4Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 3Health News:Consulting Firm Execs to Discuss Strategies for Effective Management of Specialty Drugs in AIS’s May 30 Webinar 2Health News:Brunswick Plantation & Golf Resort Named in Top 10 Golf Resorts in North Carolina 2
(Date:5/21/2013)... Fla. , May 21, 2013  Janssen ... safety results from the global Phase 3 PROMISE ... inhibitor simeprevir (TMC435) led to sustained virologic response ... in 79 percent of treatment-experienced genotype 1 chronic ... including all stages of liver fibrosis, when administered ...
(Date:5/21/2013)... , May 21, 2013 Abaxis, Inc. (NasdaqGS: ... systems, announced today that Martin Mulroy ... Stifel Annual Dental & Veterinary Conference on Wednesday, May ... be held at Le Parker Meridien Hotel in ... Abaxis Abaxis develops, manufactures, markets and sells ...
(Date:5/21/2013)...  BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTC ... stem cell based therapies for various personal applications, announced ... and CEO, will be presenting at the Marcum MicroCap ... on Thursday, May 30, 2013 at the Grand Hyatt ... York City.  Mr. Weinreb,s presentation will take place at ...
Breaking Medicine Technology:Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3
Cached News: